PH-762 Trial Delivers Complete Tumor Clearance in Final Maximum Dose Cohort
Phio Pharmaceuticals’ latest clinical update is making waves in cancer therapeutics. The company’s Phase 1b trial of its INTASYL® compound, PH-762, reached the fifth and highest dose cohort—and the pathologic results point to promising new options for skin cancer treatment. Here’s what stands out.
Significant Responses Observed: 100% Tumor Clearance in Key Patients
The trial, focused on patients with cutaneous squamous cell carcinoma (cSCC), reported striking outcomes at the final maximum dose:
- 1 patient experienced 100% tumor clearance (complete response)
- 1 patient saw over 90% tumor clearance (near complete response)
- 1 patient had over 50% tumor clearance (partial response)
All pathologic responses were assessed roughly five weeks after the initial PH-762 injection.
Cumulative Data Confirms Broad Efficacy Across Five Dose Levels
With 18 patients now treated across escalating dose levels, Phio’s PH-762 has consistently demonstrated effectiveness—especially in cSCC cases. Here’s how the data breaks down among those with cutaneous squamous cell carcinoma (n=16):
| Response Level | Number of Patients |
|---|---|
| Complete Response (100% Clearance) | 6 |
| Near Complete Response (>90% Clearance) | 2 |
| Partial Response (>50% Clearance) | 2 |
| No Response (<50% Clearance) | 6 |
Importantly, no patients in the study have experienced disease progression, underscoring the compound’s consistent benefit so far. One additional patient with metastatic Merkel cell carcinoma also saw a partial response, while one with metastatic melanoma had a non-response.
Safety Profile Remains Favorable at the Maximum Dose Level
The Safety Monitoring Committee reviewed all available safety data and confirmed no dose-limiting toxicities or serious treatment-emergent adverse effects—even at the highest dose tested, which represents a nearly 20-fold increase over the starting level. To date, all patients have tolerated PH-762 without clinically significant side effects or immune-related events. According to Phio’s medical team, the continued absence of relevant toxicities further supports the candidate’s viability as a non-surgical cancer treatment.
Potential for a New Era in Non-Surgical Skin Cancer Treatment
The INTASYL® platform aims to boost the immune system’s cancer-fighting capability by silencing PD-1, a gene implicated in immune evasion. PH-762, delivered as a series of four intratumoral injections, may provide a less invasive and highly targeted therapy option for those with advanced skin cancers. While further trials and patient enrollment are planned, the results to date set the stage for ongoing development and possibly new standards of care for cSCC and related malignancies.
What’s Next for Investors and Patients?
As the Phase 1b trial continues, eyes will remain on how PH-762 performs in additional cohorts and long-term outcomes. With zero patients progressing during the study so far and strong early responses at even the highest doses, this candidate is well-positioned for the next stages of clinical development. Patients, researchers, and investors alike may want to watch upcoming trial results for more signals of PH-762’s transformative potential in skin cancer treatment.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI